The court determined that a preliminary injunction was “an extraordinary remedy with clear requirements that Plaintiffs do not currently meet,” noting that in all of the states in the action, mifepristone remained available to prescribe and the FDA hadn’t made any indication that it intended to limit access to the drug.

Click Here To Read The Full Article